NanoViricides, Inc. (NYSE American: NNVC) has announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company noted the absence of approved vaccines or therapies specifically targeting the virus strain, highlighting the urgent need for effective interventions.
NV-387's host-targeted antiviral mechanism and oral formulation could offer significant advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola.
The company's announcement comes amid growing concerns over the spread of the Bundibugyo strain, which has shown a high fatality rate in previous outbreaks. NanoViricides believes that NV-387's unique mechanism of action, which targets host cells rather than the virus itself, may reduce the likelihood of resistance development and provide broad-spectrum activity against multiple viral strains.
According to the press release, NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's lead drug candidate, NV-387, is being developed for a range of viral infections, including RSV, COVID-19, influenza, mpox, and now potentially Ebola.
The company's novel nanoviricide technology is based on intellectual property from TheraCour Pharma, Inc., and NanoViricides holds exclusive licenses for several antiviral applications. The company has a Memorandum of Understanding with TheraCour for drug development across all antiviral infections.
NanoViricides' business model involves licensing technology from TheraCour Pharma for specific virus applications. The company's pipeline includes drug candidates for HIV/AIDS, hepatitis B and C, rabies, herpes simplex, influenza, dengue, and other viral diseases.
The company emphasized that NV-387's oral formulation could facilitate easier administration in resource-limited settings, potentially reducing the burden on healthcare systems and minimizing exposure risks for medical staff. The drug's stability at room temperature also makes it suitable for distribution in remote areas.
NanoViricides noted that the path to drug development is lengthy and requires substantial capital, and there can be no assurance that any of its candidates will show sufficient effectiveness and safety for human clinical development. However, the company remains committed to advancing NV-387 as a potential treatment for emerging viral threats.
For more information, visit the company's newsroom at https://ibn.fm/NNVC.
